CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||4 mg & 12 mg|
|Funding Request||For the first-line treatment of adult patients with unresectable Hepatocellular Carcinoma (HCC)|
|Pre Noc Submission||No|
|NOC Date||December 19, 2018|
|Submission Date||February 8, 2019|
|Submission Deemed Complete||February 25, 2019|
|Stakeholder Input Deadline ‡||February 25, 2019|
|Check-point meeting||April 12, 2019|
|pERC Meeting||June 20, 2019|
|Initial Recommendation Issued||July 5, 2019|
|Feedback Deadline ‡||July 19, 2019|
|Final Recommendation Issued||July 24, 2019|
|Notification to Implement Issued||August 9, 2019|
|Therapeutic Area||Hepatocellular Carcinoma (HCC)|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.